Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Account Payables (2020 - 2025)

Journey Medical (DERM) has disclosed Change in Account Payables for 6 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 262.86% year-over-year to -$1.2 million, compared with a TTM value of -$3.8 million through Sep 2025, up 70.51%, and an annual FY2024 reading of -$2.1 million, up 88.61% over the prior year.
  • Change in Account Payables was -$1.2 million for Q3 2025 at Journey Medical, up from -$1.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.5 million in Q3 2021 and bottomed at -$11.9 million in Q2 2023.
  • Average Change in Account Payables over 5 years is -$237000.0, with a median of $566000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables soared 736.04% in 2022, then plummeted 511.99% in 2023.
  • Year by year, Change in Account Payables stood at -$5.5 million in 2021, then surged by 153.88% to $2.9 million in 2022, then plummeted by 440.18% to -$10.0 million in 2023, then soared by 107.1% to $711000.0 in 2024, then tumbled by 268.35% to -$1.2 million in 2025.
  • Business Quant data shows Change in Account Payables for DERM at -$1.2 million in Q3 2025, -$1.6 million in Q2 2025, and -$1.6 million in Q1 2025.